Skip to main content
Happy Fridays

"Oncogenic D816V-KIT signaling in mast cells causes persistent IL-6 production"

Dr. Araceli Tobío Ageitos

Cell Cycle & Oncology Group (P1L2)

12 April 2019 17:30–18:30

Theatre Room, CiMUS

Bio

Persistent dysregulation of IL-6 production and signaling have been implicated in the pathology of various types of cancer. In systemic mastocytosis (SM), increased serum levels of IL-6 associate with disease severity. Since SM associates with the presence of a somatic gain-of-function variant in KIT, D816V-KIT, its potential role in IL-6 upregulation was studied and results obtained will be presented and discussed in this conference.

About

Graduated in Veterinary in 2008 at Universidade de Santiago de Compostela (USC) Dr. Tobío obtained three awards for her outstanding records (USC, Xunta de Galicia & Ministerio de Educación). She obtained a FPU fellowship and received her PhD in 2013 (USC). Results obtained were published in six publications as first author, four as co-author and a book chapter. In 2013 she obtained a postdoctoral "Short Term Scientific Mission (STSM)" grant (INSERM, France). Afterwards, Dr. Tobío received a postdoctoral "Juana de Vega" fellowship (INSERM, France) and established the basis of marine natural toxins use as therapeutic agents against cancer (A. Tobío, et al. Plos One, 2016). From 2015 to 2018, Dr. Tobío joined the Mast Cell Biology Section (NIH, EEUU) and her work contributed to the identification of new therapeutic targets against tumor development (A. Tobío, et al. Frontiers Immunol, 2018) and defined interleukin-6 (IL-6) as a key player in malignant cells as well as the specific oncogenic signaling pathways that drive IL-6 dysregulation in cancer cells (A. Tobío, et al. Haematologica, 2019). She joined the Cell Cycle & Oncology Group in 2019 under the supervision of Prof. Anxo Vidal.